News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Commentary

Article

December 18, 2024

Pharmaceutical Executive

Pharmaceutical Executive: December 2024
Volume44
Issue 12

Trending Forward

Author(s):

Mike Hennessy Jr.

Complementing our own industry trends and outlook coverage this month are a trio of diverse crystal-ball perspectives from guest thought leaders.

Mike Hennessy Jr., President and CEO, MJH Life Sciences

Mike Hennessy Jr., President and CEO, MJH Life Sciences

It’s that time of year again, when, as one often does, a peek into next year is in order. While making holiday plans with friends and family and wrapping gifts is, of course, on the agenda, it doesn’t stop the wonder and anticipation of what may lie around the corner in our own lives and in the world from building. The same goes for the pharma industry. And to that end, here at Pharmaceutical Executive, we decided to switch things up a bit in our coverage planning, moving our Annual Industry Outlook feature from its usual spot—the first issue of the new year—to right here in December, as a fitting capper to an event-filled 2024 for pharma and healthcare. Because, after all, you can’t properly look ahead without taking stock of what came before.

Editors of Pharm Exec do both in our annual examination of the top trends that we believe are impacting biopharmaceutical companies and the greater healthcare ecosystem the most heading into 2025. We offer deep dives into five select topics, which will likely match some of your own guesses (yes, digital and access-related issues are indeed covered).

Complementing our own trends coverage this month are a trio of crystal-ball perspectives from guest thought leaders. The first one, by authors with Simon-Kucher’s life sciences group, delves into the world of pharma sales forecasting. The experts argue that the tendency to assess value largely based on US-centric forecasts can be detrimental to product planning and decision-making. Regulatory, pricing, market access, and other important aspects from markets such as Europe, Japan, and China must be factored in.

“While US sales projections often form the backbone of global forecasts, extrapolating these figures without accounting for the unique characteristics of other markets introduces significant risks and errors,” the authors write.

The second guest piece presents an interesting take on overcoming pharma’s most pressing pain points today through newly evolved strategies in training. Author Diane Petrone, founder of Pharma Skills Lab, outlines six specific pain points, and for each one, offers tangible examples of ways companies can train and invest in their people to help navigate the challenging waters.

Not to be outdone on the outlook front is our guest op-ed by KOLs with PwC on turning back the tide of escalating healthcare costs.

Here’s to ushering in the new and building on the old. Have a wonderful, safe, and happy holiday season!

Mike Hennessy Jr. is President and CEO of MJH Life Sciences


Download Issue PDF
Articles in this issue

Pharmaceutical Executive: December 2024 Issue (PDF)
Pharmaceutical Executive: December 2024 Issue (PDF)
Trending Forward
Trending Forward
Pharma’s ‘Best-Kept Secret’
Pharma’s ‘Best-Kept Secret’
Seeking More Value, Less Cost
Seeking More Value, Less Cost
Dealmaking Dormant No More
Dealmaking Dormant No More
A Rocky Road for Regulation
A Rocky Road for Regulation
DTC's New Era of Engagement
DTC's New Era of Engagement
Holding On Tight to AI Wave
Holding On Tight to AI Wave
The Recipe for Relief: Overcoming Industry Pain Points
The Recipe for Relief: Overcoming Industry Pain Points
Pharma Forecasting: Key Markets Investors Can’t Ignore
Pharma Forecasting: Key Markets Investors Can’t Ignore
Introducing Agentic AI: Its Revolutionary Potential in Pharma
Introducing Agentic AI: Its Revolutionary Potential in Pharma
Why Healthcare Costs are Surging—And  What to Do About it
Why Healthcare Costs are Surging—And What to Do About it
Becoming More Human Through Technology, Instead of the Opposite
Becoming More Human Through Technology, Instead of the Opposite
Biopharma Needs a Health System Strategy to Secure Optimal Market Access
Biopharma Needs a Health System Strategy to Secure Optimal Market Access

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Robert Lisicki
Gen Li
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Gen Li
Related Content
Advertisement
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 2nd 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 2nd 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Stock.adobe.com
August 2nd 2025

Pharma Industry Execs React to President Trump’s 60-Day MFN Deadline

Mike Hollan
Members of the industry believe the US should remain an innovation-friendly market.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
August 2nd 2025

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 2nd 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and continued R&D investments.
FDA Approves Label Update for Novartis’ Leqvio to Enable Twice-Yearly Monotherapy for LDL-C Management in Adults with Hypercholesterolemia
August 2nd 2025

FDA Approves Label Update for Novartis’ Leqvio to Enable Twice-Yearly Monotherapy for LDL-C Management in Adults with Hypercholesterolemia

Don Tracy, Associate Editor
The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein cholesterol management.
Related Content
Advertisement
Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment
August 2nd 2025

Early Trial Success Signals Promise for GT-02287 in Parkinson’s Disease Treatment

Don Tracy, Associate Editor
Gene Mack, CEO, GAIN Therapeutics, shares how growing clinician confidence and strong early experiences helped accelerate enrollment in the company’s Phase Ib Parkinson’s disease trial.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 2nd 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Stock.adobe.com
August 2nd 2025

Pharma Industry Execs React to President Trump’s 60-Day MFN Deadline

Mike Hollan
Members of the industry believe the US should remain an innovation-friendly market.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
August 2nd 2025

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 2nd 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and continued R&D investments.
FDA Approves Label Update for Novartis’ Leqvio to Enable Twice-Yearly Monotherapy for LDL-C Management in Adults with Hypercholesterolemia
August 2nd 2025

FDA Approves Label Update for Novartis’ Leqvio to Enable Twice-Yearly Monotherapy for LDL-C Management in Adults with Hypercholesterolemia

Don Tracy, Associate Editor
The updated label no longer requires Leqvio (inclisiran) to be used in combination with statins for low-density lipoprotein cholesterol management.
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.